These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 28178721)

  • 1. Chemosaturation With Percutaneous Hepatic Perfusion in Unresectable Hepatic Metastases.
    Glazer ES; Zager JS
    Cancer Control; 2017 Jan; 24(1):96-101. PubMed ID: 28178721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemosaturation Percutaneous Hepatic Perfusion: A Systematic Review.
    Vogel A; Gupta S; Zeile M; von Haken R; Brüning R; Lotz G; Vahrmeijer A; Vogl T; Wacker F
    Adv Ther; 2017 Jan; 33(12):2122-2138. PubMed ID: 27798773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemosaturation with percutaneous hepatic perfusions of melphalan for hepatic metastases: experience from two European centers.
    Vogl TJ; Zangos S; Scholtz JE; Schmitt F; Paetzold S; Trojan J; Orsi F; Lotz G; Ferrucci P
    Rofo; 2014 Oct; 186(10):937-44. PubMed ID: 24729409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemosaturation with percutaneous hepatic perfusion for unresectable metastatic melanoma or sarcoma to the liver: a single institution experience.
    Forster MR; Rashid OM; Perez MC; Choi J; Chaudhry T; Zager JS
    J Surg Oncol; 2014 Apr; 109(5):434-9. PubMed ID: 24249545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemosaturation with percutaneous hepatic perfusion for unresectable isolated hepatic metastases from sarcoma.
    Deneve JL; Choi J; Gonzalez RJ; Conley AP; Stewart S; Han D; Werner P; Chaudhry TA; Zager JS
    Cardiovasc Intervent Radiol; 2012 Dec; 35(6):1480-7. PubMed ID: 22699779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Liver Metastases from Ocular Melanoma Using the Delcath Systems' Second-Generation Hemofiltration System: A Prospective Non-randomized Phase II Trial.
    Meijer TS; Burgmans MC; Fiocco M; de Geus-Oei LF; Kapiteijn E; de Leede EM; Martini CH; van der Meer RW; Tijl FGJ; Vahrmeijer AL
    Cardiovasc Intervent Radiol; 2019 Jun; 42(6):841-852. PubMed ID: 30767147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemosaturation with percutaneous hepatic perfusion is effective in patients with ocular melanoma and cholangiocarcinoma.
    Schönfeld L; Hinrichs JB; Marquardt S; Voigtländer T; Dewald C; Koppert W; Manns MP; Wacker F; Vogel A; Kirstein MM
    J Cancer Res Clin Oncol; 2020 Nov; 146(11):3003-3012. PubMed ID: 32564137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases.
    Hughes MS; Zager J; Faries M; Alexander HR; Royal RE; Wood B; Choi J; McCluskey K; Whitman E; Agarwala S; Siskin G; Nutting C; Toomey MA; Webb C; Beresnev T; Pingpank JF
    Ann Surg Oncol; 2016 Apr; 23(4):1309-19. PubMed ID: 26597368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of isolated hepatic perfusion via the operative and percutaneous techniques for patients with isolated and unresectable liver metastases.
    Alexander HR; Butler CC
    Cancer J; 2010; 16(2):132-41. PubMed ID: 20404610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of chemosaturation in patients with primary and secondary liver tumors.
    Kirstein MM; Marquardt S; Jedicke N; Marhenke S; Koppert W; Manns MP; Wacker F; Vogel A
    J Cancer Res Clin Oncol; 2017 Oct; 143(10):2113-2121. PubMed ID: 28634727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Over 12 Years Single Institutional Experience Performing Percutaneous Hepatic Perfusion for Unresectable Liver Metastases.
    Carr MJ; Sun J; Cohen JB; Liu J; Serdiuk AA; Stewart SR; Doobay N; Duclos A; Seal DA; Choi J; Zager JS
    Cancer Control; 2020; 27(1):1073274820983019. PubMed ID: 33372814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Percutaneous Isolated Hepatic Perfusion as a Treatment for Isolated Hepatic Metastases of Uveal Melanoma: Patient Outcome and Safety in a Multi-centre Study.
    Vogl TJ; Koch SA; Lotz G; Gebauer B; Willinek W; Engelke C; Brüning R; Zeile M; Wacker F; Vogel A; Radeleff B; Scholtz JE
    Cardiovasc Intervent Radiol; 2017 Jun; 40(6):864-872. PubMed ID: 28144756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metastatic melanoma to the liver: a contemporary and comprehensive review of surgical, systemic, and regional therapeutic options.
    Agarwala SS; Eggermont AM; O'Day S; Zager JS
    Cancer; 2014 Mar; 120(6):781-9. PubMed ID: 24301420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience.
    Artzner C; Mossakowski O; Hefferman G; Grosse U; Hoffmann R; Forschner A; Eigentler T; Syha R; Grözinger G
    Cancer Imaging; 2019 May; 19(1):31. PubMed ID: 31146793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ASO Author Reflections: Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Hepatic Metastases from Ocular Melanoma.
    Meijer TS; Burgmans MC
    Ann Surg Oncol; 2020 Dec; 27(Suppl 3):820-821. PubMed ID: 32683632
    [No Abstract]   [Full Text] [Related]  

  • 16. Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease.
    Karydis I; Gangi A; Wheater MJ; Choi J; Wilson I; Thomas K; Pearce N; Takhar A; Gupta S; Hardman D; Sileno S; Stedman B; Zager JS; Ottensmeier C
    J Surg Oncol; 2018 May; 117(6):1170-1178. PubMed ID: 29284076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolated hepatic perfusion for metastatic melanoma.
    Yamamoto M; Zager JS
    J Surg Oncol; 2014 Mar; 109(4):383-8. PubMed ID: 24166748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolated hepatic perfusion for ocular melanoma metastasis: registry data suggests a survival benefit.
    Olofsson R; Cahlin C; All-Ericsson C; Hashimi F; Mattsson J; Rizell M; Lindnér P
    Ann Surg Oncol; 2014 Feb; 21(2):466-72. PubMed ID: 24141377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Percutaneous isolated hepatic perfusion (chemosaturation) with melphalan following right hemihepatectomy in patients with cholangiocarcinoma and metastatic uveal melanoma: peri- and post-interventional adverse events and therapy response compared to a matched group without prior liver surgery.
    Dewald CLA; Becker LS; Maschke SK; Meine TC; Alten TA; Kirstein MM; Vogel A; Wacker FK; Meyer BC; Hinrichs JB
    Clin Exp Metastasis; 2020 Dec; 37(6):683-692. PubMed ID: 33034815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival.
    Marquardt S; Kirstein MM; Brüning R; Zeile M; Ferrucci PF; Prevoo W; Radeleff B; Trillaud H; Tselikas L; Vicente E; Wiggermann P; Manns MP; Vogel A; Wacker FK
    Eur Radiol; 2019 Apr; 29(4):1882-1892. PubMed ID: 30255257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.